Over the years, we have developed an expertise and so a platform, for studying targeted proteins and complete proteomes by means of structural and quantitative mass spectrometry. Biomolecules of interest, in particular in cellular signalling, are isolated from 1D/2D-electrophoresis, chromatographic purifications (high resolution HPLC/UPLC) or co-immunoprecipitations to investigate their primary structure, proteic partners, as well as post-translational modifications (proteolysis, acetylation, phosphorylation, carbamylation, ubiquitination,…).
In addition to fundamental research, we strongly focus on clinical proteomics to discover novel biomarkers by optimizing label-free quantitative DIA (SWATH) mass spectrometry. Extensive proteomic cartography of body fluids and tissues (biopsies) is established for patients presenting neurological or systemic pathologies (Erasme hospital), with the aim to improve diagnosis, prognosis and therapeutic follow-up. The development of microfluidic devices will improve sample preparation for fundamental and clinical research.
Our lab started the ULB/Erasme platform for fundamental and clinical proteomics (and metabolomics). Recent chromatographic and mass spectrometric technologies optimized by our lab are made available to other researchers via this facility for fundamental and clinical research.
For more information, please contact David Communi via email dcommuni@ulb.ac.be.
Address:
Laboratory/platform of Mass Spectrometry and Proteomics, campus Erasme, bldg. C, IRIBHM, Université Libre de Bruxelles, 808 Route de Lennik, B-1070 Brussels, Belgium.